Abstract: The present invention relates to a novel cell line isolated from a rat osteosarcoma wherein the cell line has the following characteristics: a) normal p53 gene as compared to a non-tumorigenic Sprague-Dawley rat cell control; b) normal RB-1 gene as compared to a non-tumorigenic Sprague-Dawley rat cell control; c) a normal c-myc gene as compared to a non-tumorigenic Sprague-Dawley rat cell control; d) a normal c-fos gene as compared to a non-tumorigenic Sprague-Dawley rat cell control; e) a deregulated immediate early gene response; f) a canalicular network MATRIGEL.TM.
Type:
Grant
Filed:
June 24, 1992
Date of Patent:
March 8, 1994
Assignee:
The Procter & Gamble Company
Inventors:
Claus-Jens W. Doersen, Robert J. Isfort
Abstract: The present invention relates to a novel cell line isolated from a rat osteosarcoma cell line has the following characteristics: a) a non-expressed p53 protein; b) a normal RB-1 gene; c) a 1O.times. amplified c-myc gene; d) a normal c-fos gene; e) a deregulated immediate early gene response; f) a canalicular network MATRIGEL.TM. growth pattern; g) tumorigenic in congenitally athymic mice; h) no alkaline phosphatase activity; i) an ability to produce one or more of the following growth factors: 1) an osteoblastic differentiation growth factor, 2) a non-heparin binding mitogenic growth factor, 3) a first heparin binding mitogenic growth factor, 4) a second heparin binding mitogenic growth factor, and 5) a third heparin binding mitogenic growth factor; and an ability to be serially propagated greater than sixty population doublings.The present invention also relates to growth factors having the characteristics of growth factors isolated from the rat osteosarcoma cell line.
Type:
Grant
Filed:
June 24, 1992
Date of Patent:
February 15, 1994
Assignee:
The Procter & Gamble Company
Inventors:
Claus-Jens W. Doersen, Robert J. Isfort
Abstract: The present invention relates to a novel cell line isolated from a rat osteosarcoma having the following characteristics: A) a non-expressed p53 protein; B) a normal RB-1 gene as compared to a non-tumorigenic Sprague-Dawley rat cell control; C) a normal c-fos gene as compared to a non-tumorigenic Sprague-Dawley rat cell control; D) a 50-fold amplified c-myc gene as compared to a non-tumorigenic Sprague-Dawley rat cell control; E) a monolayer MATRIGEL.TM. growth pattern; F) tumorigenic in nude mice; G) normal alkaline phosphatase activity; H) an ability to be serially propagated greater than fifty population doublings; I) an ability to produce a growth factor selected from the group consisting of: 1) a mesenchymal inhibitory growth factor; 2) a non-heparin binding mitogenic growth factor; 3) a first heparin binding mitogenic growth factor; 4) a second heparin binding mitogenic growth factor; 5) a third heparin binding mitogenic growth factor; and 6) a fourth heparin binding mitogenic growth factor.
Type:
Grant
Filed:
June 24, 1992
Date of Patent:
February 15, 1994
Assignee:
The Procter & Gamble Company
Inventors:
Claus-Jens W. Doersen, Robert J. Isfort
Abstract: The present invention relates to a novel cell line isolated from a rat osteosarcoma having the following characteristics: a) a normal p53 gene as compared to a non-tumorigenic Sprague-Dawley rat cell control; b) a normal RB-1 gene as compared to a non-tumorigenic Sprague-Dawley rat cell control; c) a normal c-myc gene as compared to a non-tumorigenic Sprague-Dawley rat cell control; d) a normal c-fos gene as compared to a non-tumorigenic Sprague-Dawley rat cell control; e) a normal immediate early gene response following mitogenic stimulation; f) a canalicular Matrigel growth pattern; g) non-tumorigenic in congenitally athymic mice; h) high levels of alkaline phosphatase activity; i) a lack of autocrine growth factor production; and j) an ability to be serially propagated greater than sixty population doublings.
Type:
Grant
Filed:
June 24, 1992
Date of Patent:
February 15, 1994
Assignee:
The Procter & Gamble Company
Inventors:
Claus-Jens W. Doersen, Robert J. Isfort
Abstract: The present invention relates to a novel cell line isolated from a rat osteosarcoma wherein the cell line has the following characteristics: a) a normal p53 gene; b) a normal RB-1 gene; c) a normal c-myc gene; d) a normal c-fos gene; e) a deregulated immediate early gene response; f) a canalicular network MATRIGEL.TM. growth pattern; g) poorly tumorigenic in congenitally athymic mice; h) no alkaline phosphatase activity; i) an ability to produce one or more of the following growth factors: 1) a non-heparin binding growth factor, 2) a first heparin binding growth factor, 3) a second heparin binding growth factor, and 4) a third heparin binding growth factor; and j) an ability to be serially propagated greater than sixty population doublings.The present invention also relates to growth factors having the characteristics of growth factors isolated from the rat osteosarcoma cell line.
Type:
Grant
Filed:
June 24, 1992
Date of Patent:
February 15, 1994
Assignee:
The Procter & Gamble Company
Inventors:
Claus-Jens W. Doersen, Robert J. Isfort
Abstract: The present invention relates to a composition for regulating hair growth comprising a safe and effective amount of the tripeptide histidyl-glycyl-glycine, or a derivative thereof, and a pharmaceutically-acceptable carrier.
Type:
Grant
Filed:
August 20, 1991
Date of Patent:
October 12, 1993
Assignee:
The Procter & Gamble Company
Inventors:
Kurt G. Kronholm, Richard J. Schwen, Mark R. Sine, Raphael Warren, Cynthia J. Wawrzyniak
Abstract: The present invnetion relates to a compositon for topical application for regulating wrinkles in mammalian skin comprising a benzofuran derivative having the structure ##STR1## wherein R.sup.1 and R.sup.2 are each independently methyl or ethyl, R.sup.3 is C.sub.1 -C.sub.4 alkyl, y is an integer from 1 to about 3 and each X is independently selected from the group consisting of Cl, Br, I, F, NO.sub.3, NO.sub.4, SO.sub.3 and SO.sub.4, and a safe and effective amount of a topical carrier.
Abstract: A composition suitable for topical application to mammalian skin or hair comprising an amount of a cell-free supernatant from a culture of dermal papilla cells sufficient to increase hair growth in mammals.
Type:
Grant
Filed:
May 22, 1990
Date of Patent:
February 25, 1992
Assignee:
The University of Dundee
Inventors:
Travis E. J. Buultjens, Stephen W. Hellens, Colin A. B. Jahoda, Roy F. Oliver, Anne P. Withers
Abstract: Disclosed is a composition for regulating hair growth comprising a safe and effective amount of a polypeptide having the structure of those derived from dermal papilla cells with characteristics of apparent isoelectric pH/molecular weight selected from the group consisting of pI 5.1/45kD, pI 5.2/43kD, pI 5.2/40kD, pI 7.3/25kD, pI 7.4/25kD, or active fragment of these polypeptides, and mixtures thereof; and a pharmaceutically-acceptable carrier.
Type:
Grant
Filed:
April 12, 1990
Date of Patent:
November 26, 1991
Assignee:
University of Dundee
Inventors:
Travis E. J. Buultjens, Colin A. B. Jahoda, Roy F. Oliver